Zilovertamab (formerly known as cirmtuzumab or UC‐961) is a monoclonal antibody to ROR1 and is in clinical trials for the treatment of leukaemias and other cancers, such as prostate cancer and lung cancer.42, 43. This evidence concerns the gene ROR1 and cancer.